Paediatrics

Baby on a respirator - RSV
#FDA #Merck #Monoclonal antibodies #Paediatrics #Respiratory syncytial virus

FDA approves Merck’s Enflonsia for RSV prevention

The US Food and Drug Administration (FDA) has approved Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season.   Enflonsia is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct,… Read More

#News #Regulatory

Neurons
#AAV #BlackfinBio #FDA #Gene therapy #Neurology #Orphan drugs #Paediatrics #Rare disease

FDA clears gene therapy trial for rare neurological disease

The US Food and Drug Administration (FDA) has cleared BlackfinBio’s Investigational New Drug (IND) application for a Phase I/II clinical trial of novel adeno-associated virus (AAV) gene therapy, BFB-101, in children with Hereditary Spastic Paraplegia Type 47 (SPG47).  The trial will be conducted in the US at Boston Children’s Hospital… Read More

#News #Regulatory

#Cancer Research UK #Gene mutation #Genetics / genomics #Oncology #Paediatrics #The Institute of Cancer Research

International team unlocks the genetic secrets of neuroblastoma

A team of international researchers have secured £1.5 ($1.9) million funding from Cancer Research UK (CRUK) to study the genetic secrets of childhood cancer neuroblastoma.  The project will be led by scientists at the University of Sheffield, alongside colleagues from The Institute of Cancer Research (ICR), Kings… Read More

#Cancer Research #News #Trending News

Pregnant woman in hospital
#Muscle atrophy #Paediatrics #Prenatal

Successful first prenatal therapy for spinal muscular atrophy

A prenatal therapy for spinal muscular atrophy (SMA) with risdiplam has shown promise in a first-of-its-kind study.  Scientists at St Jude Children’s Research Hospital led the first in utero treatment of SMA with the orally administered drug risdiplam.   More than two years after the child… Read More

#News #Trending News

A child with a cochlear implant
#Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Regeneron Pharmaceuticals

Latest DB-OTO results confirm hearing improvements

Regeneron Pharmaceuticals has revealed updated data for the investigational gene therapy DB-OTO from the Phase I/II CHORD trial in 12 children who have profound genetic hearing loss due to variants of the otoferlin (OTOF) gene.   These include 72-week results showing speech and development progress… Read More

#Editor's Choice #News

B-cells in multiple myeloma
#Cancer immunotherapy #FDA #MAIA Biotechnology #Paediatrics #Rare disease

Telomere-targeting agent granted Rare Pediatric Disease designation

The US Food and Drug Administration (FDA) has designated MAIA Biotechnology’s immunotherapy THIO for the treatment of paediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a rare paediatric disease. “THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including paediatric… Read More

#Cancer Research #News

EMA
#European Medicines Agency #Monoclonal antibodies #Paediatrics #Phase III trial #Regeneron Pharmaceuticals #Sanofi

EU Dupixent use extended to children with eosinophilic esophagitis

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year old. The approval is limited to children aged one to 11 years who weigh at least 15kg and who are inadequately controlled by, intolerant to, or who are not candidates… Read More

#News #Regulatory

Heart
#Cardiovascular disease #Corticosteroids #Duchenne muscular dystrophy #Paediatrics #Santhera Pharmaceuticals

Vamorolone demonstrates unique action as a mineralocorticoid RA

Santhera Pharmaceuticals has announced positive results from the LIONHEART study, confirming vamorolone’s action as a mineralocorticoid receptor antagonist, which the company says sets it apart from other corticosteroids. The LIONHEART study in 30 healthy adult male subjects demonstrated a statistically significant increase in the urinary sodium/potassium… Read More

#News

Saline intravenous (iv) drip in a child's hand
#Cystic fibrosis #FDA #Paediatrics #Rare disease

Three drugs secure ‘rare paediatric disease designation’ in the US

Three drugs have been granted ‘rare paediatric disease designation’ (RPDD) in the US by the Food and Drug Administration (FDA). The FDA grants RPDD for serious or life-threatening diseases that affect fewer than 200,000 people in the United States and primarily affect patients less than 18 years of age. ETD001… Read More

#News #Regulatory

#Brain cancer #Cancer Research UK #Funding #Oncology #Paediatrics

£3m boost to paediatric brain cancer research

Experts from Cancer Research UK Children’s Brain Tumour Centre of Excellence in Cambridge, UK are set to share around £3.2 ($4.2) million to find and test better and less toxic ways to treat children’s brain tumours. The funding announcement comes during Childhood Cancer Awareness Month. Read More

#Cancer Research #News

Genetics
#Africa #Childhood cancer #Nanopore sequencing #Oncology #Oxford Nanopore Technologies #Paediatrics

Consortium hopes to improve childhood cancer survival in Africa

Oxford Nanopore Technologies has joined the PROGRESS study to support improved outcomes for childhood leukaemias in Ghana. The consortium so far includes Yemaachi Biotech, Pediatric Oncology Units at Korle Bu Teaching Hospital, Komfo Anokye Teaching Hospital and Greater Accra Regional Hospital, and institutions like Newcastle University,… Read More

#Cancer Research #News

Saline intravenous (iv) drip in a child's hand
#Cancer Research Horizons #Drug discovery #LifeArc #Oncology #Paediatrics

Research consortium to focus on drug discovery for paediatric cancers

With an initial investment of £28 million in resources and funding, LifeArc and Cancer Research UK have launched a new initiative to develop medicines exclusively for children’s and young people’s cancers. C-Further will bring together researchers, clinicians, scientists and industry to provide support, finance and expertise. Read More

#Cancer Research #News

Child with retinoblastoma
#FDA #Oncology #Paediatrics #Rare disease #Theriva Biologics

Retinoblastoma therapy gets FDA rare paediatric drug designation

Theriva Biologics’ VCN-01 for retinoblastoma has been granted rare paediatric drug designation (RPDD) by the US Food and Drug Administration (FDA). The FDA grants RPDD for rare diseases (fewer than 200,000 affected persons in the United States) that are serious and life-threatening and primarily affect children ages 18 years or… Read More

#News #Regulatory

CAR-T cell therapy
#Autoimmune disease #CAR-T #Cell therapy #Lupus #Paediatrics #Universitätsklinikum Erlangen

Successful off-label use of CAR-T therapy in a child with lupus

In June 2023, a patient at Universitätsklinikum Erlangen in Germany became the first child with lupus to receive CAR-T therapy. The treatment was the last resort to slow down systemic lupus erythematosus (SLE), which is a serious autoimmune disease that was attacking the patient’s body and… Read More

#Editor's Choice #News

Premature baby in hospital
#EXO Biologics #Exosomes #Orphan drugs #Paediatrics #Phase I trial

EXO Biologics doses first cohort in MSC-based exosome clinical trial

EXO Biologics has completed dosing of the first cohort of patients in its EVENEW study, the first European Medicines Agency (EMA) authorised clinical trial involving mesenchymal stromal cell (MSC)-based exosomes. The Phase I/II clinical trial is testing the company’s lead candidate EXOB-001, developed to prevent bronchopulmonary… Read More

#News